Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Exelixis Inc (NASDAQ:EXEL)

26.13
Delayed Data
As of Nov 22
 0.00 / 0.00%
Today’s Change
14.22
Today|||52-Week Range
32.50
+75.25%
Year-to-Date
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
Nov 10 / Zacks.com - Paid Partner Content
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
Nov 09 / Zacks.com - Paid Partner Content
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
Nov 09 / Zacks.com - Paid Partner Content
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
Nov 09 / Zacks.com - Paid Partner Content
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
Nov 09 / Zacks.com - Paid Partner Content
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
Nov 09 / Zacks.com - Paid Partner Content
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
Nov 09 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close26.13
Today’s open26.40
Day’s range25.89 - 26.70
Volume1,527,414
Average volume (3 months)3,640,276
Market cap$7.7B
Dividend yield--
Data as of 4:00pm ET, 11/22/2017

Growth & Valuation

Earnings growth (last year)+65.43%
Earnings growth (this year)+275.00%
Earnings growth (next 5 years)+46.00%
Revenue growth (last year)+415.05%
P/E ratio49.3
Price/Sales19.51
Price/Book84.82

Competitors

 Today’s
change
Today’s
% change
ICLRICON PLC0.000.00%
CRLCharles River Labora...0.000.00%
PRAHPRA Health Sciences ...0.000.00%
----
Data as of 4:02pm ET, 11/22/2017

Financials

Next reporting dateFebruary 26, 2018
EPS forecast (this quarter)$0.12
Annual revenue (last year)$191.5M
Annual profit (last year)-$70.2M
Net profit margin-36.68%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Michael M. Morrissey
Executive VP, Chief Financial &
Accounting Officer
Christopher J. Senner
Corporate headquarters
South San Francisco, California

Forecasts